182 related articles for article (PubMed ID: 11699800)
21. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ
J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674
[TBL] [Abstract][Full Text] [Related]
22. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
24. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
25. Methylphenidate dosing: twice daily versus three times daily.
Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
[TBL] [Abstract][Full Text] [Related]
26. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
Brams M; Mao AR; Doyle RL
Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
[TBL] [Abstract][Full Text] [Related]
27. Analog classroom assessment of Adderall in children with ADHD.
Swanson JM; Wigal S; Greenhill LL; Browne R; Waslik B; Lerner M; Williams L; Flynn D; Agler D; Crowley K; Fineberg E; Baren M; Cantwell DP
J Am Acad Child Adolesc Psychiatry; 1998 May; 37(5):519-26. PubMed ID: 9585654
[TBL] [Abstract][Full Text] [Related]
28. Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder.
Wilson HK; Cox DJ; Merkel RL; Moore M; Coghill D
Arch Clin Neuropsychol; 2006 Dec; 21(8):797-807. PubMed ID: 17049803
[TBL] [Abstract][Full Text] [Related]
29. Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine.
Whitley HP; Moorman KL
Pharmacotherapy; 2007 Oct; 27(10):1440-5. PubMed ID: 17896898
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
31. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Short EJ; Manos MJ
J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290
[TBL] [Abstract][Full Text] [Related]
32. Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects.
Ahmann PA; Theye FW; Berg R; Linquist AJ; Van Erem AJ; Campbell LR
Pediatrics; 2001 Jan; 107(1):E10. PubMed ID: 11134474
[TBL] [Abstract][Full Text] [Related]
33. Sustained-release methylphenidate: new preparations. New pharmaceutical forms: a slight advantage for a small number of children.
Prescrire Int; 2004 Dec; 13(74):203-6. PubMed ID: 15612099
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
35. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures.
Pelham WE; Swanson JM; Furman MB; Schwindt H
J Am Acad Child Adolesc Psychiatry; 1995 Nov; 34(11):1504-13. PubMed ID: 8543519
[TBL] [Abstract][Full Text] [Related]
36. Adderall XR: long acting stimulant for single daily dosing.
Sallee FR; Smirnoff AV
Expert Rev Neurother; 2004 Nov; 4(6):927-34. PubMed ID: 15853519
[TBL] [Abstract][Full Text] [Related]
37. More objective tools should be employed to objectify the therapeutic response.
Yang R; Mao S; Li R; Zhao Z
J Dev Behav Pediatr; 2010; 31(9):733. PubMed ID: 21057259
[No Abstract] [Full Text] [Related]
38. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T; Faraone S; Prince J; Gerard K; Doyle R; Parekh A; Kagan J; Bearman SK
Arch Gen Psychiatry; 2001 Aug; 58(8):775-82. PubMed ID: 11483144
[TBL] [Abstract][Full Text] [Related]
39. Managing stimulant medication for attention-deficit/hyperactivity disorder.
Wender EH
Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
[No Abstract] [Full Text] [Related]
40. Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study.
Cutler AJ; Suzuki K; Starling B; Balakrishnan K; Komaroff M; Castelli M; Meeves S; Childress AC
J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):89-97. PubMed ID: 35020462
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
